Resources

Biotech meetings and communication

One of the less-fun aspects of biotech, and the working world in general, are meetings. Most often they can be good for driving the team’s progress, but they can also be redundant or just unnecessary. For those impactful ones, there are certain approaches that ensure the right information is communicated,…

Management training on the fly

Last year I defended my PhD and was lucky enough to get an awesome job as the first scientist at an early clinical stage biotech. We have since hired a few more people, one of whom is a research technician direct report. He and I have worked together for about…

Biologic and Biosimilar Biomanufacturing

Therapeutics typically come as small molecules and biologics. Small molecules are what people typically think of when they think of the pharmaceutical industry: they have been around for much longer than the first biologic, insulin, that was first available in 1982; they are most often much cheaper to produce; and…

Biotech Product Concept Formulation Framework

Last week I wrote an introduction to some of the basic concepts related to starting a biotech company. But let’s back up and talk about the most basic but essential fundamental: how to go about thinking through a product concept. There are several crucial factors to consider to determine the…

Biotech Startup Concepts

I currently work at a small but clinical-stage biotech company, where I work alongside our founder (an entrepreneur) and a consultant (another entrepreneur) who has his own company on the side that focuses on a protein-based treatment for Muscular Dystrophy. Because of I am surrounded by a startup-y, entrepreneurial feel,…

What to Expect at a Scientific Conference

I recently had the privilege of attending a small rare disease conference in Vienna, Austria. I have been to several other conferences, but nevertheless I found myself wondering what exactly to expect from this one. When I was in graduate school getting my PhD, I found that I frequently asked…

Small Molecule Drug Discovery

This week’s topic focuses on a narrower area of biotech/pharma early drug discovery. Most approved drugs are small molecules. Classically, these drugs abide by Lipinski’s Rule of 5. However, many final drug candidates that enter the clinic do not exactly follow these rules. One may make the obvious assertion here…

Biotech Options Trading

When people think of investing, they think of buying and selling individual stocks, mutual funds, index funds, ETFs, bonds, etc. And I will say right off the bat, that the vast majority of investors, especially in biotech, are better off with these more standard trading strategies than options trading. The…

Biotech Research and Development Collaborations

Small and early-stage biotech companies often have severely limited resources for performing critical proof of concept (PoC) experiments. Sometimes, very early companies don’t even have in-house scientific capabilities. In these cases, outsourcing research is essential to producing value. Contract research organizations (CROs) and contract manufacturing organizations (CMOs) can fill in…

From the clinic to FDA approval

Last week, I wrote about the preclinical side of drug discovery: from target discovery through screening and optimization, IND-enabling studies, and finally the components of the IND itself. So say the IND is approved, then what? Here, I will discuss the general path through clinical trials. Note along the way…